OncoMatch/Clinical Trials/NCT06253871
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Is NCT06253871 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies IAM1363 for her2 mutation-related tumors.
Treatment: IAM1363 — This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Urothelial Carcinoma
Colorectal Cancer
Gastric Cancer
Esophageal Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) altered
Have relapsed/refractory HER2-altered malignancy
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
Have progression of disease after the last systemic therapy, or be intolerant of last systemic therapy
Lab requirements
Blood counts
adequate baseline hematologic function
Kidney function
adequate baseline renal function
Liver function
adequate baseline liver function
Cardiac function
left ventricular ejection fraction (lvef) ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCSD Moores Cancer Center · La Jolla, California
- USC Norris Comprehensive Cancer Center · Los Angeles, California
- University of Colorado Cancer Center · Aurora, Colorado
- University of Miami · Miami, Florida
- Comprehensive Hematology Oncology · St. Petersburg, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06253871 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy.
Does this trial require ERBB2?
Yes, ERBB2 altered is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify